Madrigal and CSPC Pharmaceutical sign up to $2 billion licensing deal

Madrigal Pharmaceuticals

30/07/2025 10:08

July 30 (Reuters) - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has entered a global license agreement for up to $2 billion with CSPC Pharmaceutical 1093.HK to develop an oral GLP-1 drug for a type of liver disease.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)

 ((Sriparna.Roy@thomsonreuters.com;))